The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small Molecules
Open accessAbstract
Summary The high rate of clinical response to protein kinase-targeting drugs matched to cancer patients with specific genomic alterations has prompted efforts to use cancer cell-line (CCL) profiling to identify additional biomarkers of small-molecule sensitivities. We have quantitatively measured the sensitivity of 242 genomically characterized CCLs to an Informer Set of 354 small molecules that target many nodes in cell circuitry, uncovering protein dependencies that: 1) associate with specific cancer-genomic alterations and 2) can be targeted by small molecules. We have created the Cancer Therapeutics Response Portal (www.broadinstitute.org/ctrp) to enable users to correlate genetic features to sensitivity in individual lineages and control for confounding factors of CCL profiling. We report a candidate dependency, associating activating mutations in the oncogene β-catenin with sensitivity to the Bcl2-family antagonist, navitoclax. The resource can be used to develop novel therapeutic hypotheses and accelerate discovery of drugs matched to patients by their cancer genotype and lineage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Regularization and Variable Selection Via the Elastic Net
Zou, H., & Hastie, T. (2005) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2005.00503.x · Cited by 20,957
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.042 · Cited by 18,691
Self-citationNew Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1107 · Cited by 9,766
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Self-citationMolecular signatures database (MSigDB) 3.0
Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., & Mesirov, J. P. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr260 · Cited by 7,111
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
Liu, J., Farmer, J. D., Lane, W. S., Friedman, J., Weissman, I., & Schreiber, S. L. (1991) · Cell · doi:10.1016/0092-8674(91)90124-h · Cited by 4,116 · cited 2×
“Compounds having different structures but targeting the same protein (e.g., cyclosporin A and tacrolimus targeting calcineurin; Liu et al., 1991) and compounds having differential selectivity toward distinct members of a protein family (e.g., histone deacetylases; Pan et al., 2012) were included to…”
BackgroundSelf-citationABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
The NCI60 human tumour cell line anticancer drug screen
Shoemaker, R. H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1951 · Cited by 2,620
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Chemokine signaling via the CXCR2 receptor reinforces senescence
Acosta, J. C., O'Loghlen, A., Banito, A., Guijarro, M. V., Augert, A., Raguz, S., Fumagalli, M., Da Costa, M., Brown, C., Popov, N., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.038 · Cited by 1,801
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771
Jho, E.-H., Zhang, T., Domon, C., Joo, C.-K., Freund, J.-N., & Costantini, F. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.4.1172-1183.2002 · Cited by 1,678
A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K.-K., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.05.006 · Cited by 1,017
Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer.
Sparks, A. B., Morin, P. J., Vogelstein, B., & Kinzler, K. W. (1998) · PubMed · Cited by 1,008
β-Catenin-Driven Cancers Require a YAP1 Transcriptional Complex for Survival and Tumorigenesis
Rosenbluh, J., Nijhawan, D., Cox, A. G., Li, X., Neal, J. T., Schafer, E. J., Zack, T. I., Wang, X., Tsherniak, A., Schinzel, A. C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.11.026 · Cited by 757 · cited 10×
“Increased b -catenin activity has also been linked to enhanced expression of BCL2 and BCL2L1 (Kaga et al., 2006; Rosenbluh et al., 2012) and to suppression of BAX-mediated apoptosis (Wang et al., 2009).”
InfluentialRegulation of Wnt Signaling during Adipogenesis
Bennett, C. N., Ross, S. E., Longo, K. A., Bajnok, L., Hemati, N., Johnson, K. W., Harrison, S. D., & MacDougald, O. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204527200 · Cited by 741
Control of p70 S6 kinase by kinase activity of FRAP in vivo
Brown, E. J., Beal, P. A., Keith, C. T., Chen, J., Bum Shin, T., & Schreiber, S. L. (1995) · Nature · doi:10.1038/377441a0 · Cited by 705
Self-citationGandhi, L., Camidge, D. R., Ribeiro de Oliveira, M., Bonomi, P., Gandara, D., Khaira, D., Hann, C. L., McKeegan, E. M., Litvinovich, E., Hemken, P. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6208 · Cited by 603
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents
Sharma, S. V., Haber, D. A., & Settleman, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2820 · Cited by 586
Subtype and pathway specific responses to anticancer compounds in breast cancer
Heiser, L. M., Sadanandam, A., Kuo, W.-L., Benz, S. C., Goldstein, T. C., Ng, S., Gibb, W. J., Wang, N. J., Ziyad, S., Tong, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018854108 · Cited by 475
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Chen, Z., Cheng, K., Walton, Z., Wang, Y., Ebi, H., Shimamura, T., Liu, Y., Tupper, T., Ouyang, J., Li, J., et al. (2012) · Nature · doi:10.1038/nature10937 · Cited by 446 · cited 2×
“The top-ranked gene, STK11, has been implicated in resistance to docetaxel in a murine model of KRAS mutant lung cancer (Chen et al., 2012).”
BackgroundSelf-citationCheung, H. W., Cowley, G. S., Weir, B. A., Boehm, J. S., Rusin, S., Scott, J. A., East, A., Ali, L. D., Lizotte, P. H., Wong, T. C., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109363108 · Cited by 423
Self-citationCorcoran, R. B., Cheng, K. A., Hata, A. N., Faber, A. C., Ebi, H., Coffee, E. M., Greninger, P., Brown, R. D., Godfrey, J. T., Cohoon, T. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.007 · Cited by 377
Classification of gene microarrays by penalized logistic regression
Zhu, J. (2004) · Biostatistics · doi:10.1093/biostatistics/5.3.427 · Cited by 372
Lefebvre, C., Rajbhandari, P., Alvarez, M. J., Bandaru, P., Lim, W. K., Sato, M., Wang, K., Sumazin, P., Kustagi, M., Bisikirska, B. C., et al. (2010) · Molecular Systems Biology · doi:10.1038/msb.2010.31 · Cited by 370
McDermott, U., Sharma, S. V., Dowell, L., Greninger, P., Montagut, C., Lamb, J., Archibald, H., Raudales, R., Tam, A., Lee, D., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707498104 · Cited by 356
The Ins and Outs of MYC Regulation by Posttranslational Mechanisms
Vervoorts, J., Lüscher-Firzlaff, J., & Lüscher, B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.r600017200 · Cited by 260
Sartore-Bianchi, A., Di Nicolantonio, F., Nichelatti, M., Molinari, F., De Dosso, S., Saletti, P., Martini, M., Cipani, T., Marrapese, G., Mazzucchelli, L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007287 · Cited by 259
Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance
Gonzalez de Castro, D., Clarke, P. A., Al-Lazikani, B., & Workman, P. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.237 · Cited by 239
Development of small-molecule probes that selectively kill cells induced to express mutant RAS
Weïwer, M., Bittker, J. A., Lewis, T. A., Shimada, K., Yang, W. S., MacPherson, L., Dandapani, S., Palmer, M., Stockwell, B. R., Schreiber, S. L., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.09.047 · Cited by 237
Self-citationJu, J., Hong, J., Zhou, J.-N., Pan, Z., Bose, M., Liao, J., Yang, G.-Y., Liu, Y. Y., Hou, Z., Lin, Y., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1949 · Cited by 219
New molecularly targeted therapies for lung cancer
Sun, S., Schiller, J. H., Spinola, M., & Minna, J. D. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31809 · Cited by 201
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Cited by 180
Kaga, S., Zhan, L., Altaf, E., & Maulik, N. (2005) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2005.09.009 · Cited by 150
Biological pathway analysis by ArrayUnlock and Ingenuity Pathway Analysis
Jiménez-Marín, Á., Collado-Romero, M., Ramírez-Boo, M., Arce, C., & Garrido, J. J. (2009) · BMC Proceedings · doi:10.1186/1753-6561-3-s4-s6 · Cited by 138
Corcoran, R. B., Settleman, J. E., & Engelman, J. A. (2011) · Oncotarget · doi:10.18632/oncotarget.262 · Cited by 133
Targeted Therapies for Lung Cancer: Clinical Experience and Novel Agents
Larsen, J. E., Cascone, T., Gerber, D. E., Heymach, J. V., & Minna, J. D. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e31823e701a · Cited by 115
TR3/Nur77 in colon cancer cell apoptosis.
Wilson, A. J., Arango, D., Mariadason, J. M., Heerdt, B. G., & Augenlicht, L. H. (2003) · PubMed · Cited by 114
Self-citationβ-Catenin Promotes Survival of Renal Epithelial Cells by Inhibiting Bax
Wang, Z., Havasi, A., Gall, J. M., Mao, H., Schwartz, J. H., & Borkan, S. C. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009030253 · Cited by 105
Yoon, J., Koo, K.-H., & Choi, K.-Y. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3058 · Cited by 92
Tahir, S. K., Wass, J. A. H., Joseph, M. K., Devanarayan, V., Hessler, P., Zhang, H., Elmore, S. W., Kroeger, P. E., Tse, C., Rosenberg, S. H., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0651 · Cited by 78
PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.
Smalley, K. S. M. (2010) · PubMed · Cited by 72
Wilson, A. J., Holson, E. B., Wagner, F. F., Zhang, Y.-L., Fass, D. M., Haggarty, S. J., Bhaskara, S., Hiebert, S. W., Schreiber, S. L., & Khabele, D. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.6.15956 · Cited by 53
Self-citationEGF receptor mutations in lung cancer: From humans to mice and maybe back to humans
Arteaga, C. L. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.05.014 · Cited by 51
Janne, P. A., Shaw, A. T., Pereira, J. R., Jeannin, G., Vansteenkiste, J., Barrios, C. H., Franke, F. A., Grinsted, L. M., Smith, P. D., Zazulina, V., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.7503 · Cited by 36
Bootstrap hypothesis testing in regression models
Paparoditis, E., & Politis, D. N. (2005) · Statistics & Probability Letters · doi:10.1016/j.spl.2005.04.057 · Cited by 36
Selective Histone Deacetylase Inhibitors
Pan, H., Cao, J., & Xu, W. (2012) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152012800228814 · Cited by 26
Cited by
Regulation of Ferroptotic Cancer Cell Death by GPX4
Yang, W. S., SriRamaratnam, R., Welsch, M. E., Shimada, K., Skouta, R., Viswanathan, V. S., Cheah, J. H., Clemons, P. A., Shamji, A. F., Clish, C. B., et al. (2014) · Cell · doi:10.1016/j.cell.2013.12.010 · Cited by 7,713
Self-citationDrug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
FSP1 is a glutathione-independent ferroptosis suppressor
Doll, S., Freitas, F. P., Shah, R., Aldrovandi, M., da Silva, M. C., Ingold, I., Goya Grocin, A., Xavier da Silva, T. N., Panzilius, E., Scheel, C. H., et al. (2019) · Nature · doi:10.1038/s41586-019-1707-0 · Cited by 3,341
A Landscape of Pharmacogenomic Interactions in Cancer
Iorio, F., Knijnenburg, T. A., Vis, D. J., Bignell, G. R., Menden, M. P., Schubert, M., Aben, N., Gonçalves, E., Barthorpe, S., Lightfoot, H., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.017 · Cited by 2,090
DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer
Mao, C., Liu, X., Zhang, Y., Lei, G., Yan, Y., Lee, H., Koppula, P., Wu, S., Zhuang, L., Fang, B., et al. (2021) · Nature · doi:10.1038/s41586-021-03539-7 · Cited by 1,900
Metadata
- Authors
- Basu, A., Bodycombe, N. E., Cheah, J. H., Price, E. V., Liu, K., Schaefer, G. I., Ebright, R. Y., Stewart, M. L., Ito, D., Wang, S., Bracha, A. L., Liefeld, T., Wawer, M., Gilbert, J. C., Wilson, A. J., Stransky, N., Kryukov, G. V., Dancik, V., Barretina, J., Garraway, L. A., Hon, C. S.-Y., Munoz, B., Bittker, J. A., Stockwell, B. R., Khabele, D., Stern, A. M., Clemons, P. A., Shamji, A. F., & Schreiber, S. L.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2013-08
- Volume
- 154
- Issue
- 5
- Pages
- 1151-1161
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2152883907
- Cited by
- 833
- References
- 51
- FWCI
- 10.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.